Idealite (Diacerein)

Diacerein is used in the management of osteoarthritis, a degenerative joint disease affecting cartilage and subchondral bone.

• Osteoarthritis of the knee: reduces pain and slows cartilage loss.
• Osteoarthritis of the hip: improves joint function and mobility.
• Secondary osteoarthritis: helps control symptoms and delay disease progression.

• Diacerein exerts its effect by inhibiting interleukin‑1β activity, which curtails the production of matrix‑metalloproteinases and other catabolic mediators. This leads to reduced cartilage degradation, decreased synovial inflammation, and preservation of joint structure, thereby alleviating pain and improving function in osteoarthritic joints.

Diacerein may cause a range of adverse reactions, most of which are related to the gastrointestinal tract or skin.

Common Side Effects

• Diarrhea: loose stools that may be mild to moderate.
• Abdominal pain: cramping or discomfort in the stomach area.
• Nausea: feeling of queasiness, sometimes with vomiting.
• Dyspepsia: indigestion or heartburn.
• Flatulence: excess gas causing bloating.
• Constipation: difficulty passing stools.

Serious or Rare Side Effects

• Hepatic enzyme elevation: potential liver function abnormalities.
• Severe allergic reactions: rash, itching, or swelling that may require medical attention.
• Stevens‑Johnson syndrome: rare but serious skin disorder.
• Severe dehydration: from prolonged diarrhea.
• Neutropenia: low white‑blood‑cell count increasing infection risk.
• Severe skin rash: extensive erythema or blistering.

Before initiating therapy with Idealite, several safety considerations should be observed.

• Assess liver function: obtain baseline hepatic enzymes and monitor periodically.
• Monitor gastrointestinal tolerance: advise patients to report persistent or severe diarrhea.
• Use with caution in the elderly: increased susceptibility to GI adverse events.
• Avoid in patients with known hypersensitivity to diacerein or related compounds.
• Do not co‑administer with strong CYP2C9 inhibitors without medical supervision.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Diacerein can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Concurrent use with NSAIDs: heightened risk of gastrointestinal toxicity.
• Co‑administration with potent CYP2C9 inhibitors: may increase diacerein plasma concentrations.
• Combination with anticoagulants: potential for increased bleeding.

Moderate Interactions (Monitor Closely)

• Use with other disease‑modifying osteoarthritis drugs: monitor overall efficacy and side‑effect profile.
• Concurrent use with diuretics: watch for electrolyte disturbances.
• Combination with antidiabetic agents: possible alterations in glucose control.